2016

BRAIN TUMORS: FROM BIOLOGY TO THERAPY 2016

 

MONDAY, 27 June 2016

08:00 - 09:00 REGISTRATION

09:00 - 09:10 Opening remarks

09:10 - 12:50 Origins of brain tumors and glioblastoma heterogeneity (chairs: Dolores Hambardzumyan, Bozena Kaminska)

  • Surgical strategies to interrogate the genomics of glioblastoma (Colin Watts; University of Cambridge UK)
  • Molecular characterization of CNS primitive neuroektodermal tumors (Dominik Sturm; University Hospital Heidelberg and German Cancer Research Center, Germany)
  • COFFEE BREAK
  • A cell of origin - based strategy to decipher glioblastoma biology (Lene Uhrbom; University of Uppsala, Sweden)
  • Resolving genetic and phenotypic heterogeneity in glioblastoma (Simone Niclou; Luxemburg Institute of Health, Luxemburg)
  • Identification of diverse astrocytic populations and their emergence during glioma induced seizures (Benjamin Deneen; Baylor College of Medicine, Houston, USA)

LUNCH BREAK AND SPONSORED LECTURE

  • SeqCap EZ MedExome Target Enrichment Kit. Coverage with Confidance (Adam Olejnik; Roche Diagnostics Polska)

14:00 - 17:20 Brain tumor therapy (chairs: Zvi Cohen, Pawel Nauman)

  • Harnessing nanomedicine as a new approach for  GBM treatment (Zvi Cohen; Sheba Medical Center, Tel Ashomer, Israel)
  • A role for new therapeutic targets and re-purposed/re-formulated drugs in glioma therapy (Geoffrey Pilkington; University of Portsmouth, UK)
  • Glioblastoma microenvironment (Joan Seoane; Vall d’Hebron Institute of Oncology, Spain)
  • COFFEE BREAK
  • ORAL PRESENTATIONS FROM SUBMITTED ABSTRACTS:
    • In human GBM, the pro-angiogenic phenotype of microglia/macrophages depends on the infiltration rate of granulocytes (Susan Brandenburg; Charité - Universitätsmedizin Berlin, Germany)
    • Apelin signaling controls glioblastoma neo-vascularization and growth (Roland E. Kälin; University Clinics, LMU Munich, Germany)
    • Tumor-derived osteopontin via its RGD motif is responsible for the protumorigenic reprogramming of glioma- infiltrating microglia/macrophages and glioma growth (Dominika Pszczolkowska; Nencki Institute of Experimental Biology, Poland)
  • Identifying new drugs for primary and secondary brain tumours using cMap (Rolf Bjerkvig; University of Bergen, Norway)

18:30–21:00 WELCOME RECEPTION AT STASZIC PALACE (Palac Staszica, Nowy Świat 72, Warsaw)

DAY 2

TUESDAY, 28 June 2016

 09:00 - 12:00 Signalling in brian tumors (chairs: Lene Uhrbom, Aleksandra Ellert-Miklaszewska)

  • A contemporary molecular view of diffuse gliomas with implications for diagnosis (Daniel J. Brat; Winship Cancer Institute of Emory University, Atlanta, USA)
  • Combinatorial therapy design in glioblastoma models (Ksenya Shchors; Swiss Federal Institute of Technology, Switzerland)
  • COFFEE BREAK
  • Role of CK2 in GBM and autoimmunity (Etty (Tika) Benveniste; University of Alabama, Birmingham, USA)
  • Glioma-derived osteopontin/SPP1 supports glioma stem-like cells and blocks anti-tumor responses (Bozena Kaminska; Nencki Institute, Warsaw, Poland)

LUNCH BREAK

13:10 - 17:00 Glioma immunology and immunotherapy (chairs: Tika Benveniste, Katarzyna Kotulska)

  • Cellular immunotherapy targeting malignant gliomas (Duane Mitchell; University of Florida, USA)
  • The role of pro-inflammatory chemokine network in gliomagenesis (Dolores Hambardzumyan; Emory University School of Medicine, Atlanta, USA)
  • Immunological changes during tumor progression from primary to recurrent glioblastoma (Christel Herold-Mende; University Hospital Heidelberg, Germany)
  • COFFEE BREAK
  • Targeting IDH1R132H for glioma immunotherapy (Michael Platten; University Hospital Heidelberg and German Cancer Research Center, Germany)
  • Glioblastoma immunotherapy (Gaetano Finocchiaro; IRCCS Foundation "C. Besta" Neurological Institute, Milan, Italy)

17:00 - 19:00 POSTER SESSION (wine and cheese by the posters)

20:00 - 23:00 GALA DINNER (by invitation)

DAY 3

WEDNESDAY, 29 June 2016

 09:00 - 14:10 Glioma signaling and biology (chairs: Frank AE Kruyt, Cristina Limatola)

  • mTOR inhibitors in tuberous sclerosis: from brain tumor treatment to the control of systemic disease (Katarzyna Kotulska; The Children’s Memorial Health Institute, Poland)
  • Epigenetic Deregulation in Glioma, Biomarkers and New Opportunities (Monika Hegi; University Hospital Lausanne, Switzerland)
  • Molecular motors are drivers of proliferation and invasion in glioblastoma (Steven Rosenfeld; Cleveland Clinic, USA)
  • COFFEE BREAK
  • Differentiation and invasion in glioblastoma (Frank AE Kruyt; University of Groningen, Netherlands)
  • Environmental and pharmacological tools to reprogram microglia/macrophages infiltrating brain tumor (Cristina Limatola; Sapienza University, Rome, Italy)
  • Tuberous Sclerosis Complex neuropathology requires glutamate-cysteine ligase (Jacek Jaworski; International Institute of Molecular and Cellular Biology, Warsaw, Poland)

13:30 - 14:10 FAREWELL LUNCH

14:14  GUIDED TOUR: Warsaw sightseeing